269 related articles for article (PubMed ID: 20505956)
1. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.
Einhorn LH; Grunberg SM; Rapoport B; Rittenberg C; Feyer P
Support Care Cancer; 2011 Mar; 19 Suppl 1():S1-4. PubMed ID: 20505956
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.
Einhorn LH; Rapoport B; Koeller J; Grunberg SM; Feyer P; Rittenberg C; Aapro M
Support Care Cancer; 2005 Feb; 13(2):112-6. PubMed ID: 15480812
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
4. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
[TBL] [Abstract][Full Text] [Related]
5. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Aapro M
N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
[No Abstract] [Full Text] [Related]
6. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
8. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
9. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
10. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
11. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Kris MG; Hesketh PJ; Herrstedt J; Rittenberg C; Einhorn LH; Grunberg S; Koeller J; Olver I; Borjeson S; Ballatori E
Support Care Cancer; 2005 Feb; 13(2):85-96. PubMed ID: 15565277
[TBL] [Abstract][Full Text] [Related]
12. Consensus regarding multiple day and rescue antiemetic therapy.
De Mulder PH; Roila F; Kris MG; Marty MM
Support Care Cancer; 1998 May; 6(3):248-52. PubMed ID: 9629878
[TBL] [Abstract][Full Text] [Related]
13. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
15. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
17. Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: guideline update and results of the Perugia consensus conference.
Roila F; Herrstedt J; Gralla RJ; Tonato M
Support Care Cancer; 2011 Mar; 19 Suppl 1():S63-5. PubMed ID: 21188425
[No Abstract] [Full Text] [Related]
18. Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Hashizume J; Higuchi N; Sato K; Kodama Y; Matsunaga N; Sakamoto T; Yamaguchi K; Nakamura T; Kitahara T; Sasaki H
Biol Pharm Bull; 2016; 39(4):611-4. PubMed ID: 27040634
[TBL] [Abstract][Full Text] [Related]
19. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Rapoport BL; Herrstedt J; Snow RC; Radhakrishnan V; Saito M; Navari RM; Smit T
Support Care Cancer; 2023 Dec; 32(1):36. PubMed ID: 38105286
[TBL] [Abstract][Full Text] [Related]
20. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]